Published in J Clin Psychiatry on February 01, 2005
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia (MELT) | NCT02796144
Reducing the Weight of Overweight Schizophrenia Patients | NCT00158366
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull (2009) 3.78
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry (2014) 1.94
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull (2007) 1.69
Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry (2009) 1.65
Lifestyle interventions for adults with serious mental illness: a systematic literature review. Psychiatr Serv (2010) 1.45
Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev (2007) 1.40
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. Schizophr Bull (2015) 1.21
A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. Int J Obes (Lond) (2010) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act (2011) 1.08
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry (2012) 1.06
Racial and ethnic differences in diabetes mellitus among people with and without psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Gen Hosp Psychiatry (2011) 0.93
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med (2008) 0.93
Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. Compr Psychiatry (2013) 0.91
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res (2007) 0.90
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry (2008) 0.87
Effectiveness of a psychosocial weight management program for individuals with schizophrenia. J Behav Health Serv Res (2014) 0.87
The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry (2010) 0.84
The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS One (2014) 0.83
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Psychiatry (2012) 0.83
A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity. J Gen Intern Med (2017) 0.81
Improving Weight in People with Serious Mental Illness: The Effectiveness of Computerized Services with Peer Coaches. J Gen Intern Med (2017) 0.81
Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study. J Clin Psychopharmacol (2012) 0.81
Primary care-based educational interventions to decrease risk factors for metabolic syndrome for adults with major psychotic and/or affective disorders: a systematic review. Syst Rev (2013) 0.81
Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia. Biol Res Nurs (2010) 0.80
Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry (2008) 0.80
Interventions for the metabolic syndrome in schizophrenia: a review. Ther Adv Endocrinol Metab (2012) 0.80
Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain. J Clin Psychiatry (2005) 0.79
Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry (2010) 0.78
The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. Community Ment Health J (2013) 0.78
Barriers and facilitators of a healthy lifestyle among persons with serious and persistent mental illness: perspectives of community mental health providers. Community Ment Health J (2014) 0.78
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res (2013) 0.77
Implementation of a weight loss program for Latino outpatients with severe mental illness. Community Ment Health J (2012) 0.77
The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry. Prim Care Companion J Clin Psychiatry (2007) 0.77
Preventive counseling for chronic disease: missed opportunities in a community mental health center. Psychosomatics (2012) 0.76
Changes in body weight, body composition and cardiovascular risk factors after long-term nutritional intervention in patients with severe mental illness: an observational study. BMC Psychiatry (2011) 0.76
The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry (2016) 0.76
Perceptions and dietary intake of self-described healthy and unhealthy eaters with severe mental illness. Community Ment Health J (2014) 0.76
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. J Gen Intern Med (2016) 0.75
Health Education and Activity - Lessening The Inequalities in mental health (HEA - LTI mental health). BMJ Qual Improv Rep (2017) 0.75
Metabolic syndrome, serious mental illnesses & lifestyle. Indian J Med Res (2016) 0.75
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology (Berl) (2005) 0.75
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med (2002) 5.65
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry (2009) 3.26
Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response. Eur Neuropsychopharmacol (2013) 2.14
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res (2006) 1.93
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry (2009) 1.61
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology (2006) 1.59
A preliminary meta-analysis of the child behavior checklist in pediatric bipolar disorder. Biol Psychiatry (2003) 1.58
Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes. Psychiatr Serv (2010) 1.58
Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med (2007) 1.57
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry (2015) 1.55
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2006) 1.31
Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull (2003) 1.28
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord (2009) 1.20
Are older antipsychotic drugs obsolete? BMJ (2006) 1.19
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry (2010) 1.04
The heterogeneity of schizophrenia in disease states. Schizophr Res (2004) 1.04
Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res (2003) 1.02
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry (2012) 1.02
Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophr Res (2010) 1.02
Caudate nucleus volume and cognitive performance: Are they related in childhood psychopathology? Biol Psychiatry (2006) 1.00
Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res (2006) 0.98
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord (2009) 0.97
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol (2010) 0.96
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res (2005) 0.96
Gender and schizophrenia. Psychopharmacol Bull (2007) 0.96
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol (2008) 0.95
Anterior cingulate volume in pediatric bipolar disorder and autism. J Affect Disord (2007) 0.94
Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res (2005) 0.94
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med (2008) 0.93
Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr Res (2005) 0.91
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res (2007) 0.90
Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics (2002) 0.89
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr (2005) 0.89
Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry (2008) 0.88
Evaluation of familial influences on the course and severity of schizophrenia among US and Indian cases. Soc Psychiatry Psychiatr Epidemiol (2004) 0.88
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat (2012) 0.88
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res (2008) 0.88
Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatr Dis Treat (2010) 0.87
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther (2003) 0.87
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol (2010) 0.86
Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early Interv Psychiatry (2010) 0.86
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. Ann Gen Psychiatry (2009) 0.86
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry (2004) 0.85
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry (2013) 0.85
Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study). Schizophr Res (2013) 0.84
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis (2007) 0.84
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry (2011) 0.83
Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999. Value Health (2002) 0.82
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res (2012) 0.80
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry (2014) 0.79
Predictors of aripiprazole treatment continuation in hospitalized patients. J Clin Psychiatry (2008) 0.79
Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull (2007) 0.79
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci (2011) 0.79
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol (2013) 0.79
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry (2007) 0.79
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innov Clin Neurosci (2012) 0.79
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol (2016) 0.79
Adherence to Diabetes Medication in Individuals with Schizophrenia: A Systematic Review of Rates and Determinants of Adherence. Clin Schizophr Relat Psychoses (2014) 0.78
Diabetes resolution following discontinuation of a second-generation antipsychotic. Clin Schizophr Relat Psychoses (2013) 0.78
Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics (2002) 0.78
Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: preliminary study. Diabetes Metab Syndr Obes (2012) 0.77
A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol (2014) 0.77
Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial. Int Clin Psychopharmacol (2010) 0.77
Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord (2010) 0.76
Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias. J Am Geriatr Soc (2004) 0.76
Letter to the editor. J Minim Invasive Gynecol (2010) 0.75
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 0.75
Methodological issues in a comparative study of ziprasidone and risperidone. J Clin Psychiatry (2006) 0.75
Early Alzheimer's disease. N Engl J Med (2004) 0.75
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder. J Clin Psychopharmacol (2016) 0.75
Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder. J Nerv Ment Dis (2017) 0.75
Cognitive remediation for individuals with psychosis in a supported education setting: a pilot study. Rehabil Res Pract (2012) 0.75
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. Innov Clin Neurosci (2011) 0.75
Dietary intake of patients with schizophrenia. Psychiatry (Edgmont) (2005) 0.75
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. Int Clin Psychopharmacol (2016) 0.75
Response to Drs. Citrome and Ketter. Eur Neuropsychopharmacol (2013) 0.75
Gerard E. Hogarty (1935--2006): combining science and humanism to improve the care of persons with schizophrenia. Schizophr Bull (2007) 0.75
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Hum Psychopharmacol (2007) 0.75
Evaluation of a treatment manual for risperidone long-acting injectable. Community Ment Health J (2007) 0.75
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. J Affect Disord (2009) 0.75
Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder. J Affect Disord (2013) 0.75
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials. Psychopharmacol Bull (2008) 0.75
Assessing online dietary information for people with schizophrenia. Psychiatr Serv (2014) 0.75
Physical activity and sedentary behavior measured objectively and subjectively in overweight and obese adults with schizophrenia or schizoaffective disorders. J Clin Psychiatry (2015) 0.75